5S rRNA modificator - CAS 1415238-77-5
Catalog number: 1415238-77-5
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C9H8N2O2
Molecular Weight:
176.17
COA:
Inquire
Targets:
Others
Description:
5S rRNA modificator is a suitable electrophile for 2’-hydroxyl acylation on structured RNA molecules, yielding accurate structural information comparable to that obtained with existing probes; 5S rRNA RNA modification.
Purity:
>98%
Synonyms:
5S rRNA modificator
MSDS:
Inquire
InChIKey:
OOBPIWAAJBRELM-UHFFFAOYSA-N
InChI:
InChI=1S/C9H8N2O2/c1-7-8(2-5-13-7)9(12)11-4-3-10-6-11/h2-6H,1H3
Canonical SMILES:
CC1=C(C=CO1)C(=O)N2C=CN=C2
1.RNomics and Modomics in the halophilic archaea Haloferax volcanii: identification of RNA modification genes.
Grosjean H1, Gaspin C, Marck C, Decatur WA, de Crécy-Lagard V. BMC Genomics. 2008 Oct 9;9:470. doi: 10.1186/1471-2164-9-470.
BACKGROUND: Naturally occurring RNAs contain numerous enzymatically altered nucleosides. Differences in RNA populations (RNomics) and pattern of RNA modifications (Modomics) depends on the organism analyzed and are two of the criteria that distinguish the three kingdoms of life. If the genomic sequences of the RNA molecules can be derived from whole genome sequence information, the modification profile cannot and requires or direct sequencing of the RNAs or predictive methods base on the presence or absence of the modifications genes.
2.Direct regulation of tRNA and 5S rRNA gene transcription by Polo-like kinase 1.
Fairley JA1, Mitchell LE, Berg T, Kenneth NS, von Schubert C, Silljé HH, Medema RH, Nigg EA, White RJ. Mol Cell. 2012 Feb 24;45(4):541-52. doi: 10.1016/j.molcel.2011.11.030. Epub 2012 Jan 25.
Polo-like kinase Plk1 controls numerous aspects of cell-cycle progression. We show that it associates with tRNA and 5S rRNA genes and regulates their transcription by RNA polymerase III (pol III) through direct binding and phosphorylation of transcription factor Brf1. During interphase, Plk1 promotes tRNA and 5S rRNA expression by phosphorylating Brf1 directly on serine 450. However, this stimulatory modification is overridden at mitosis, when elevated Plk1 activity causes Brf1 phosphorylation on threonine 270 (T270), which prevents pol III recruitment. Thus, although Plk1 enhances net tRNA and 5S rRNA production, consistent with its proliferation-stimulating function, it also suppresses untimely transcription when cells divide. Genomic instability is apparent in cells with Brf1 T270 mutated to alanine to resist Plk1-directed inactivation, suggesting that chromosome segregation is vulnerable to inappropriate pol III activity.
3.Small ubiquitin-like modifier (SUMO)-mediated repression of the Xenopus Oocyte 5 S rRNA genes.
Malik MQ1, Bertke MM1, Huber PW2. J Biol Chem. 2014 Dec 19;289(51):35468-81. doi: 10.1074/jbc.M114.609123. Epub 2014 Nov 3.
The 5 S rRNA gene-specific transcription factor IIIA (TFIIIA) interacts with the small ubiquitin-like modifier (SUMO) E3 ligase PIAS2b and with one of its targets, the transcriptional corepressor, XCtBP. PIAS2b is restricted to the cytoplasm of Xenopus oocytes but relocates to the nucleus immediately after fertilization. Following the midblastula transition, PIAS2b and XCtBP are present on oocyte-type, but not somatic-type, 5 S rRNA genes up through the neurula stage, as is a limiting amount of TFIIIA. Histone H3 methylation, coincident with the binding of XCtBP, also occurs exclusively on the oocyte-type genes. Immunohistochemical staining of embryos confirms the occupancy of a subset of the oocyte-type genes by TFIIIA that become positioned at the nuclear periphery shortly after the midblastula transition. Inhibition of SUMOylation activity relieves repression of oocyte-type 5 S rRNA genes and is correlated with a decrease in methylation of H3K9 and H3K27 and disruption of subnuclear localization.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 12279-41-3 ACTH (1-39)

ACTH (1-39)
(CAS: 12279-41-3)

ACTH (1-39) is the major regulator of adrenal cortex function and could stimulate the synthesis of steroidal hormones.

CAS 141505-33-1 Levosimendan

Levosimendan
(CAS: 141505-33-1)

Levosimendan is a calcium sensitizer acting through calcium-dependent binding to cardiac troponin C (cTnC)

CAS 3615-24-5 Ramifenazone

Ramifenazone
(CAS: 3615-24-5)

Ramifenazone is a non-steroidal anti-inflammatory synthetic reagent.

CAS 112559-91-8 Hydroxy Itraconazole

Hydroxy Itraconazole
(CAS: 112559-91-8)

Hydroxy Itraconazole, a metabolite of Itraconazole, is a ketoconazole analogue which could be used as an antimycotic.

Lecithin from Soybean
(CAS: 8057-53-2)

Lecithin is a surfactant. It has emulsification and lubricant properties. It is a major component of biological membranes and can be obtained from a variety of ...

JTV 519 fumarate
(CAS: 1883549-36-7)

The fumarate salt form of JTV 519, which has been found to be a Ryanodine receptor (RyR) inhibitor and also could be a useful intermediate.

CAS 257292-29-8 KF 38789

KF 38789
(CAS: 257292-29-8)

KF 38789 is a selective inhibitor of P-selectin-mediated cell adhesion with IC50 value of 1.97 μM. It shows no effects on E-selectin-mediated and L-selectin- ad...

CAS 16980-89-5 Bucladesine sodium salt

Bucladesine sodium salt
(CAS: 16980-89-5)

Bucladesine is a cell-permeable, cyclic nucleotide derivative that mimics the action of endogenous cyclic adenosine monophosphate (cAMP) and is a phosphodiester...

Chemical Structure

CAS 1415238-77-5 5S rRNA modificator

Quick Inquiry

Verification code

Featured Items